Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma
- 1 May 1999
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 188 (5) , 522-530
- https://doi.org/10.1016/s1072-7515(99)00018-6
Abstract
The optimal toxic reaction of the normal tissues in perfused limbs after isolated limb perfusion (ILP) is unknown. Theoretically, more severe limb toxicity could reflect a concomitant increased toxic effect to the tumor and improved outcomes. We determined whether there is a relation between limb toxicity and treatment outcomes after ILP for recurrent limb melanoma. Among 252 patients with recurrent melanoma of the limbs, treatment outcomes in 192 patients (76%) with no or mild acute limb toxicity were compared with those in 60 (24%) with more severe reactions. Multivariate analysis was used to identify prognostic factors for complete response, limb recurrence-free interval, and survival. Among 112 patients with measurable disease, 65 patients (58%) had a complete response and 27 (42%) experienced a relapse in the perfused limb. For complete response, uninvolved regional lymph nodes (p = 0.0025) and ILP using tumor necrosis factor-alpha (p = 0.0076) appeared to be favorable prognostic factors in multivariate analysis. There was no evidence of a relation between limb toxicity and complete response either in univariate (p = 0.16) or multivariate analysis (p = 0.46). For limb recurrent-free interval, only the number of lesions was a significant prognostic factor (p = 0.047); limb toxicity was not (p = 0.095). In 140 patients with recurrent melanoma excised before or at the moment of ILP, independent prognostic factors for survival were gender, the number of positive nodes, and stage of disease. There was no relation between limb toxicity and survival in either univariate (p = 0.53) or multivariate analysis (p = 0.94). Forty-eight (34%) of the 140 patients had a relapse in the perfused limb. No prognostic factors for limb recurrent-free interval could be identified; limb toxicity was not related to relapse time in univariate or multivariate analyses (p = 0.16 and p = 0.14, respectively). More severe acute limb toxicity is not associated with improved outcomes. One should aim at grade II toxicity (slight erythema or edema, compatible with complete recovery) at the most to increase the therapeutic ratio of ILP.Keywords
This publication has 22 references indexed in Scilit:
- Thirty-five years of isolated limb perfusion for melanoma: Indications and resultsBritish Journal of Surgery, 1996
- Determinants of acute regional toxicity following isolated limb perfusion for melanomaMelanoma Research, 1996
- Severe acute regional toxicity after normothermic or ??mild?? hyperthermic isolated limb perfusion with melphalan for melanomaMelanoma Research, 1995
- High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancerEuropean Journal Of Cancer, 1995
- Potentiation of dna‐adduct formation and cytotoxicity of platinum‐containing drugs by low pHInternational Journal of Cancer, 1993
- Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limbEuropean Journal Of Cancer, 1993
- Isolated limb perfusion with chemotherapeutic agents for melanoma: A reevaluation of drug dosimetryEuropean Journal of Cancer and Clinical Oncology, 1989
- Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusionCancer, 1989
- Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactionsEuropean Journal of Cancer and Clinical Oncology, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958